Clinical trial · Observational
LINE: Treatment Patterns in postmenopausaL Women With Hormone Receptor Positive Breast Cancer
NCT01561443CI-TRIAL-00020483LINEcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is the first study focused on features/stereotypes of the first and second-line treatment patterns in Russia, comparison of different treatments, and determination of effective hormone treatment patterns in real-life practice with evaluation of pharmacoeconomic aspects. Study LINE is designed for collection of data on clinical effectiveness of second-line hormone treatment and quality of life in patients with breast cancer(BC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Local Advanced or Metastatic Postmenopausal Breast Cancer | Breast Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Collection of data of routine regimens of hormone therapy in postmenopausal women with hormone receptor-positive, locally advanced or metastatic breast cancer
- timeFrame
- 2 years
Secondary outcomes (8)
- measure
- Quality of life (QoL): the extent of reduction in QoL deficit from 1 visit
- timeFrame
- 2 years
- measure
- The extent of reduction anxiety inventory
- timeFrame
- 2 years
- measure
- Effectiveness: Tumor regression; number of patients with complete response (CR), partial response (PR) or stable disease
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Postmenopausal women with hormone receptor-positive breast cancer: * Recurrence after the adjuvant hormone therapy; * Or initially inoperable locally advanced or metastatic breast cancer progressed after the first line hormone therapy; * Ability to read and write and complete questionnaires Provision of written informed consent * Patients who have already been prescribed therapy with the above-mentioned lines and who can continue on the prescribed therapy in the investigator's opinion according to his/her regular clinical practice and cure Exclusion Criteria: * As per study design, to ensure high validity of data and to obtain accurate information on real-life practice, * Patients currently participating in other clinical studies will not be included in this study
References
Publications (0)
Data not yet available
No reference posted for this study.